The findings, published in the March issue of Gastroenterology, revealed no significant difference in positive predictive value between average risk patients who received a guaiac fecal occult blood test in the first round and those who received a fecal immunochemical test in the first round.
Researchers said, however, that “no large difficulties are to be expected should a switch from a guaiac-based program to a FIT-based program be desired in screening programs currently using guaiac tests.”
Related Articles on GI and Endoscopy:
Kentucky Public-Private Partnership to Fund Colon Cancer Screenings for the Uninsured
Regulators Work to Limit Weight Loss Pill Qnexa, Citing Safety Concerns
Dr. Joseph Brasco: 5 Points on Fecal Microbiota Transplant in an ASC
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
